Navigation Links
Einstein researchers discover 2 new ways to kill TB
Date:3/21/2010

of TB bacteria grown in Petri dishes as well as in infected mice.

"We were amazed when we knocked out GlgE that we saw this DNA damage response," says Dr. Jacobs. "That's usually a very effective way to kill bacteria, when you start damaging the DNA."

The researchers discovered a second way of killing TB after observing a crucial connection between their novel alpha glucan pathway and a second pathway that also synthesizes alpha glucans.

When the researchers knocked out one of the other enzymes in their novel pathway, the pathway's shutdown didn't kill the bacteria; similarly, inactivating an enzyme called Rv3032 in the second alpha glucan pathway failed to kill the microbes. But inactivating both of those enzymes caused what the researchers term synthetic lethality: two inactivations that separately were nonlethal but together cause bacterial death.

"The bacteria that cause TB need to synthesize alpha glucans," notes Dr. Jacobs. "And from the bacterial point of view, you can't knock out both of these alpha glucan pathways simultaneously or you're dead. So if we were to make drugs against GlgE and Rv3032, the combination would be extremely potent. And since TB bacteria need both of those alpha glucan pathways to live, it's very unlikely that this combination therapy would leave behind surviving bacteria that could develop into resistant strains."

Dr. Jacobs adds that findings from this study could also enhance treatment of diseases caused by other species of mycobacteria. Leprosy, for example, which still occurs in the U.S. and other countries, is caused by a mycobacterium related to TB. Treating leprosy now involves using several different drugs, some of which are also used to treat tuberculosis.


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
2. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
3. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
4. In scientific first, Einstein researchers correct decline in organ function associated with old age
5. Einstein researchers develop a new way to study how breast cancer spreads
6. Einstein researchers develop technique to count messages made by single genes
7. Einstein scientists receive $10 million NIH grant
8. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
9. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
10. NIH funds research center for womens reproductive health at Einstein
11. Einstein researchers devise a fast and sensitive way to detect ricin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
(Date:5/26/2015)... May 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced ... convened at Shutters on the Beach in ... status of the Company,s innovative Metronomic Biofeedback Pump (MBP), ... deliver chemotherapy over time to a target site of ... and biofeedback system in real-time.  ...
(Date:5/26/2015)... 26, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... study protocol for the company,s Phase IIb trial of ... and Drug Administration (FDA). The submission was made under ... The Phase IIb study of ORMD-0801 for type ...
(Date:5/26/2015)... Just the characterization of being a ... need does not guarantee immediate acceptance. In particular, ... many prior failures is often met with significant skepticism. ... an irony that is often an unappreciated aspect of ... Asymmetrex has found that building acceptance of ...
(Date:5/22/2015)... 2015  Actavis plc (NYSE: ACT ) today ... Appeals for the Second Circuit has issued a ruling ... Company to continue distribution of NAMENDA ® (memantine ...   "While we are disappointed by ... to continue our strong efforts to convey the significant ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8
... , , RESEARCH TRIANGLE PARK, ... announced a partnership with Max Healthcare to open a Phase I/IIa ... This proof of concept unit will allow Pharmaceutical, Biotech & Device ... process across multiple therapeutic areas quickly and with the highest quality. ...
... , AUSTIN, Texas, Sept. 23 TOPAZ Technologies, a ... industry, today announced it has 15 customers who have upgraded to ... is focused on the management and approval process for Institutional Animal ... to address the research and compliance needs of the IACUC, TOPAZ ...
... , , BOSTON, Sept. ... (Nasdaq: PRXL ) and a leading global life ... released its second annual study on the state of the ... PAREXEL Consulting analysis, contained in the new white paper entitled ...
Cached Biology Technology:Max Neeman International to Open Phase I/IIa Unit 2TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions 2PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 2PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 3PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 4PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era 5
... MBS Start up kit. Includes configured Laptop ... of 2 MultiBlock satellite thermal cyclers ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
... The Lambda 10-2 is a microprocessor ... impressive speed coupled with exceptionally smooth ... for research applications involving fluorescence microscopy, ... any application requiring rapid and accurate ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... α-Amylase is a hydrolytic enzyme ... a mixture of glucose, maltose, maltotriose ... various fluids of the human,body are ... microbial,a-amylases are important enzymes for industry.4, ...
Biology Products: